Literature DB >> 9787166

Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia.

M C Minnema1, D Pajkrt, W A Wuillemin, D Roem, W K Bleeker, M Levi, S J van Deventer, C E Hack, H ten Cate.   

Abstract

Evidence of factor XI (FXI) activation in vivo is scarce. In addition, it remains uncertain whether thrombin, factor XIIa (FXIIa), or perhaps another protease is responsible for FXI conversion. We investigated the activation of FXI in eight healthy volunteers after infusion of a low dose of endotoxin (4 ng/kg of body weight). Activation of prekallikrein FXII, FXI, and prothrombin was measured with sensitive enzyme-linked immunosorbent assays (ELISAs), and FXI activation was measured with a novel enzyme capture assay that detects noncomplexed FXIa. Activation of FXI was apparent with a significant plasma peak level of noncomplexed FXIa of 10 to 11 pmol/L at 1 and 2 hours after endotoxin infusion, followed by a gradual increase in FXIa-FXIa inhibitor complexes, measured in the ELISAs, with a summit of 11 to 15 pmol/L at 6 and 24 hours, respectively. In accordance with previous studies, thrombin generation was detected 1 hour after endotoxin infusion to become maximal after 3 to 4 hours. In contrast, we did not find any evidence of contact activation, because markers of activation of prekallikrein and FXII remained undetectable. From the FXIa data a theoretical model was constructed which suggested that inhibition of FXIa does not take place in the plasma compartment, but is localized on a surface. These data provide the first evidence for FXI activation in low-grade endotoxemia and suggest that FXI is activated independently of FXII. Copyright 1998 by The American Society of Hematology

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9787166

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis.

Authors:  Deyan Luo; Frank M Szaba; Lawrence W Kummer; Lawrence L Johnson; Erik I Tucker; Andras Gruber; David Gailani; Stephen T Smiley
Journal:  Infect Immun       Date:  2011-10-17       Impact factor: 3.441

Review 2.  Pathogenic mechanism and modeling of neuroferritinopathy.

Authors:  Anna Cozzi; Paolo Santambrogio; Maddalena Ripamonti; Ermanna Rovida; Sonia Levi
Journal:  Cell Mol Life Sci       Date:  2021-01-13       Impact factor: 9.261

3.  Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia.

Authors:  M J Mooberry; R Bradford; E L Hobl; F C Lin; B Jilma; N S Key
Journal:  J Thromb Haemost       Date:  2016-04-05       Impact factor: 5.824

4.  The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII.

Authors:  D Zamolodchikov; T Renné; S Strickland
Journal:  J Thromb Haemost       Date:  2016-02-29       Impact factor: 5.824

5.  Feedback activation of factor XI by thrombin does not occur in plasma.

Authors:  Donna L Pedicord; Dietmar Seiffert; Yuval Blat
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-25       Impact factor: 11.205

6.  Peptidoglycan induces disseminated intravascular coagulation in baboons through activation of both coagulation pathways.

Authors:  Narcis I Popescu; Robert Silasi; Ravi S Keshari; Alanson Girton; Tarea Burgett; Sacha S Zeerleder; David Gailani; Andras Gruber; Florea Lupu; K Mark Coggeshall
Journal:  Blood       Date:  2018-06-19       Impact factor: 25.476

7.  Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant.

Authors:  Mostafa Hamada; Varsha Bhakta; Sara N Andres; William P Sheffield
Journal:  Front Cardiovasc Med       Date:  2021-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.